Aim: To assess the effect of empagliflozin on cardiovascular (CV) risk in patients with type 2 diabetes (T2DM) through a meta-analysis of data from eight placebo-controlled trials.
1
Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of T2DM. 4, 5 In Phase III placebo-controlled trials, empagliflozin given as monotherapy or add-on therapy consistently improved glycaemic control and was associated with improvements in weight and blood pressure. [6] [7] [8] [9] [10] [11] [12] [13] In some trials, empagliflozin was associated with an increase in high-density lipoprotein (HDL) cholesterol [6] [7] [8] [9] and low-density lipoprotein (LDL) cholesterol. 7 In the EMPA-REG OUTCOME trial in patients with T2DM and high CV risk, empagliflozin given in addition to standard of care was associated with significant reductions in 3-point major adverse CV events [MACE, a composite of CV death, non-fatal myocardial infarction (MI) and non-fatal stroke], CV death, all-cause mortality, hospitalization for heart failure and the composite of heart failure hospitalization or CV death versus placebo. 14, 15 The benefit of empagliflozin with respect to CV death and the composite endpoint of hospitalization for heart failure or CV death was consistent across subgroups defined by baseline characteristics. 14, 15 Here we assess the effect of empagliflozin on CV risk via a meta-analysis of data from eight randomized, placebo-controlled Phase III trials including EMPA-REG OUTCOME.
2 | METHODS
| Study design and patients
A meta-analysis was conducted using data from all randomized placebo-controlled trials of empagliflozin in patients with T2DM of >12 weeks' duration. These studies investigated empagliflozin for 24 weeks as monotherapy (EMPA-REG MONO), 6 add-on to metformin (EMPA-REG-MET), 7 add-on to metformin plus a sulphonylurea (EMPA-REG-METSU) 8 or add-on to pioglitazone with or without metformin (EMPA-REG PIO), 9 for 78 weeks as add-on to basal insulin (EMPA-REG BASAL), 10 for 52 weeks as add-on to multiple daily injections of insulin (EMPA-REG MDI), 11 for 52 weeks as add-on to a variety of background therapies in patients with stage 2-4 chronic kidney disease (EMPA-REG RENAL) 12 or in addition to standard of care in patients at high CV risk (EMPA-REG OUTCOME) over a median observation time of 3.1 years 14 (Table S1 , Supporting Information). In addition, a meta-analysis of data from patients at low/medium CV risk was performed using data from these trials excluding EMPA-REG OUTCOME. Practice. All patients provided written informed consent.
| Endpoints and measurements
The primary endpoint of the meta-analysis was the composite of CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalization for unstable angina (4-point MACE). The composite of CV death, non-fatal MI and non-fatal stroke (3-point MACE) was a secondary endpoint. Pre-specified tertiary endpoints included CV death, MI (fatal and non-fatal), non-fatal MI, stroke (fatal and non-fatal), non-fatal stroke (ischaemic and haemorrhagic), hospitalization for heart failure, hospitalization for unstable angina and all-cause mortality. A composite endpoint of heart failure hospitalization or CV death was analysed post-hoc. The outcomes were prespecified to be analysed in each trial, except for the composite of hospitalization for heart failure or CV death. All suspected CV events were prospectively adjudicated by Clinical Events Committees blinded to treatment allocation and the CV endpoints were based on adjudicated CV events.
| Statistical analyses
All analyses were exploratory and based on individual patient data.
The prespecified primary analysis assessed the risk for the primary, secondary and tertiary endpoints with empagliflozin (pooled 10 and 25 mg groups) versus placebo in randomized patients who received at least one dose of study drug, expressed as hazard ratios (HR) and 95% confidence intervals (CIs). This analysis was based on a Cox regression model adjusted for treatment (empagliflozin or placebo) and study. To investigate possible heterogeneity of the results across studies, post-hoc Cox regression analyses were conducted, including a treatment-by-study interaction factor. Patients without outcomes were censored at the time they were last known to be free of the event, but no later than the planned observational period in the trial.
The overall significance level for the meta-analysis was α = 0.025 (2.5%), one-sided. No adjustment for multiple tests was performed.
Nominal p-values are reported. Additional analyses were performed on the individual empagliflozin dose groups versus placebo.
Descriptive statistics were calculated as incidence (number of patients with an event as a percentage of all patients analysed) and incidence rate (number of patients with an event divided by the time the patient was at risk of contributing an event to the analysis, calculated per 1000 patient-years). Estimates of cumulative incidence function, corrected for death as a competing risk, were used to present time to CV death with empagliflozin and placebo. Kaplan-Meier estimates were used to present time to all-cause mortality with empagliflozin and placebo.
3 | RESULTS
| Patients
The analysis of all trials comprised 3835 patients who received placebo, 3629 patients who received empagliflozin 10 mg and 3828 patients who received empagliflozin 25 mg. Patient demographics and baseline characteristics were balanced across the treatment groups (Table 1 and Table S2 
| CV events
In the meta-analysis comprising patients at low/medium CV risk (placebo-controlled Phase III studies) or high CV risk (EMPA-REG OUT-COME), empagliflozin reduced the risk of the primary endpoint of MACE, CV death, all-cause mortality and hospitalization for heart failure missed significance, with confidence intervals crossing unity ( Figure 6 ). The composite endpoint of hospitalization for heart failure or CV death occurred at a significantly lower rate with empagliflozin than with placebo ( Figure 6 ). There was no statistically significant heterogeneity across studies for any endpoint in Cox regression analyses, including a treatment-by-study interaction factor.
| DISCUSSION
In EMPA-REG OUTCOME, empagliflozin reduced the risk of CV outcomes in patients with T2DM at high CV risk. 14 This meta-analysis of eight trials comprising EMPA-REG OUTCOME and seven trials conducted in patients at low/medium CV risk extends those results by
showing that CV outcomes were consistent between the high and low/medium CV risk patients and across the trials conducted in low/ medium risk patients. We consider patients enrolled in trials other than EMPA-REG OUTCOME to be at low/medium CV risk based on event rates for 3-point MACE of 4.6 to 28.7 per 1000 patient-years in the placebo group, compared with 43.9 per 1000 patient-years in the placebo group of the EMPA-REG OUTCOME trial. Hazard ratios and 95% confidence intervals (CI) for 4-point major adverse cardiovascular events (MACE) with empagliflozin (pooled) versus placebo in the meta-analysis of all trials, the meta-analysis excluding EMPA-REG OUTCOME and the individual trials. Cox regression analysis.
These analyses were designed to investigate the effect of empagliflozin on clinical outcomes, not the mechanisms behind the effects.
These may include reductions in hyperglycaemia, weight and systolic blood pressure, [6] [7] [8] [9] [10] [11] [12] [13] [14] term studies limit the conclusions on long-term outcomes. In addition, FIGURE 5 Hazard ratios and 95% confidence intervals (CI) for 3-point major adverse cardiovascular events (MACE) with empagliflozin (pooled) versus placebo in the meta-analysis of all trials, the meta-analysis excluding EMPA-REG OUTCOME and the individual trials. Cox regression analysis. FIGURE 6 Incidence of cardiovascular events and all-cause mortality with empagliflozin (pooled) versus placebo in the meta-analysis excluding EMPA-REG OUTCOME.
observation was not continued after discontinuation of study drug other than in EMPA-REG OUTCOME, so a true intention-to-treat analysis could not be conducted.
In conclusion, a meta-analysis of data from eight randomized placebo-controlled trials suggests that empagliflozin is associated with a reduced risk of CV morbidity and mortality in patients with T2DM, including those at low/medium or high CV risk.
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